- Benign Prostatic Hyperplasia
- Hormone Therapy
- Genomic Testing
- Next-Generation Imaging
- UTUC
- OAB and Incontinence
- Genitourinary Cancers
- Kidney Cancer
- Men's Health
- Pediatrics
- Female Urology
- Sexual Dysfunction
- Kidney Stones
- Urologic Surgery
- Bladder Cancer
- Benign Conditions
- Prostate Cancer
Dr. Schmidt recaps key bladder cancer research from SUO 2023
Bogdana Schmidt, MD, MPH, outlines key bladder cancer research that was presented at this year’s Society of Urologic Oncology Annual Meeting.
In this video, Bogdana Schmidt, MD, MPH, outlines key bladder cancer research that was presented at this year’s Society of Urologic Oncology Annual Meeting, held in Washington DC. Schmidt is a urologic oncology at Huntsman Cancer Institute – University of Utah Health, Salt Lake City. Schmidt discusses the following abstracts:
LBA (Tyson et al): First results from BOND-003, a Phase 3 Study of Intravesical Cretostimogene Grenadenorepvec Monotherapy for Patients with High-risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Abstract 164 (Boorjian et al): Efficacy of intravesical nadofaragene firadenovec for patients with BCG-unresponsive carcinoma in situ of the bladder: 36-month follow-up from a phase 3 trial
Abstract 153 (Das et al): Comparing white light versus blue light cystoscopy recurrence outcomes among non-muscle invasive bladder cancer patients in an equal access setting: a propensity scored matched analysis
Abstract 146 (Fleshner et al): Consistent performance of Bladder EpiCheck for NMIBC surveillance in the USA and European pivotal studies and in real world studies
Abstract 57 (Corsi et al): Neoadjuvant chemotherapy and radical nephroureterectomy (RNU) vs RNU alone for upper tract urothelial carcinoma: a multi-institutional cohort analysis (ROBUUST Collaborative)
